Treating refractory and metastatic lung cancer

Dr. Roy Herbst of Yale University discusses early results for MPDL3280A, a new PD-L1 antibody for the treatment of non-small cell lung cancer; he also gives his take on other exciting lung cancer data being presented at the ASCO 2013 annual meeting.